Overview
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
Indication
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.
Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Hypertension
- Ureteric calculus
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/05/04 | Phase 2 | Suspended | |||
2019/10/23 | Phase 2 | Recruiting | |||
2018/01/12 | Phase 1 | Withdrawn | |||
2017/11/13 | Phase 2 | Active, not recruiting | San Francisco Veterans Affairs Medical Center | ||
2017/06/05 | Phase 3 | Completed | |||
2016/12/12 | Phase 2 | Completed | |||
2016/09/15 | Phase 4 | Completed | |||
2016/05/27 | Phase 1 | Completed | |||
2015/09/30 | Phase 2 | UNKNOWN | First Affiliated Hospital of Harbin Medical University | ||
2015/09/02 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| State of Florida DOH Central Pharmacy | 53808-1017 | ORAL | 2 mg in 1 1 | 1/3/2015 | |
| DOH CENTRAL PHARMACY | 53808-1107 | ORAL | 4 mg in 1 1 | 1/15/2019 | |
| ROERIG | 0049-2760 | ORAL | 2 mg in 1 1 | 1/20/2022 | |
| Accord Healthcare Inc. | 16729-414 | ORAL | 2 mg in 1 1 | 3/15/2023 | |
| NuCare Pharmaceuticals, Inc. | 66267-377 | ORAL | 4 mg in 1 1 | 1/6/2023 | |
| A-S Medication Solutions | 50090-3143 | ORAL | 8 mg in 1 1 | 11/30/2021 | |
| Apotex Corp. | 60505-0096 | ORAL | 8 mg in 1 1 | 5/25/2023 | |
| Aurobindo Pharma Limited | 59651-892 | ORAL | 1 mg in 1 1 | 3/22/2024 | |
| Aidarex Pharmaceuticals LLC | 33261-658 | ORAL | 4 mg in 1 1 | 12/30/2013 | |
| A-S Medication Solutions | 50090-6298 | ORAL | 4 mg in 1 1 | 7/31/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| CARDURA TABLET 2 mg | SIN05014P | TABLET | 2 mg | 8/16/1990 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Doxazosin mesilate Tablets 4 mg | 238897 | Medicine | A | 5/25/2015 | |
| Doxazosin mesilate Tablets 1 mg | 238895 | Medicine | A | 5/25/2015 | |
| Doxazosin mesilate Tablets 8 mg | 238898 | Medicine | A | 5/25/2015 | |
| Doxazosin mesilate Tablets 2 mg | 238896 | Medicine | A | 5/25/2015 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| DOXAZOSINA CINFA 4 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 63068 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
| DOXAZOSINA CINFA 2 mg COMPRIMIDOS EFG | Laboratorios Cinfa S.A. | 63067 | COMPRIMIDO | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
| DOXAZOSINA NEO AUROVITAS SPAIN 4 mg COMPRIMIDOS DE LIBERACION PROLONGADA EFG | Aurovitas Spain, S.A.U. | 70679 | COMPRIMIDO DE LIBERACIÓN PROLONGADA | Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.